Investigational Drug Information for AZD-5363
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the drug development status for AZD-5363?
AZD-5363 is an investigational drug.
There have been 33 clinical trials for AZD-5363. The most recent clinical trial was a Phase 3 trial, which was initiated on September 15th 2021.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Ovarian Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.
There are one hundred and thirty-four US patents protecting this investigational drug and one international patent.
Summary for AZD-5363
|US Patent Applications||483|
|WIPO Patent Applications||418|
|Japanese Patent Applications||169|
|Clinical Trial Progress||Phase 3 (2021-09-15)|
Recent Clinical Trials for AZD-5363
|Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2||AstraZeneca||Phase 3|
|Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2||Botswana Ministry of Health||Phase 3|
|Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2||Botswana Harvard AIDS Institute Partnership||Phase 3|
Clinical Trial Summary for AZD-5363
Top disease conditions for AZD-5363
Top clinical trial sponsors for AZD-5363
US Patents for AZD-5363
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AZD-5363||See Plans and Pricing||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||See Plans and Pricing|
|AZD-5363||See Plans and Pricing||Treatment of ophthalmic conditions by selectively removing senescent cells from the eye||Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)||See Plans and Pricing|
|AZD-5363||See Plans and Pricing||Polymeric nanoparticles and methods of making and using same||Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY)||See Plans and Pricing|
|AZD-5363||See Plans and Pricing||Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide||AstraZeneca AB (Sodertalje, SE)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
International Patents for AZD-5363
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AZD-5363||Australia||AU2015244171||2034-04-11||See Plans and Pricing|
|AZD-5363||Australia||AU2015244179||2034-04-11||See Plans and Pricing|
|AZD-5363||Canada||CA2945128||2034-04-11||See Plans and Pricing|
|AZD-5363||Canada||CA2945129||2034-04-11||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|